Abstract
Prognostic factors for excellent response (ER) to initial therapy in patients with papillary thyroid cancer (PTC) have not been fully established. This prospective multicenter study investigated the response to initial therapy in 506 PTC patients from nine centers in China. All participants underwent total or near-total thyroidectomy with lymph node dissection and subsequent radioiodine (RAI) therapy. Univariate and multivariable logistic regression analyses identified extrathyroidal extension (ETE), the number of metastatic lymph nodes, and preablative-stimulated thyroglobulin (Ps-Tg) as independent prognostic factors for ER. Receiver operating characteristic (ROC) curves determined optimal cutoff values for the number of metastatic lymph nodes: 5 for the entire population and 13 for pathological N1b patients. These findings suggest that higher metastatic lymph node counts and elevated Ps-Tg levels are significant predictors of failing to achieve an ER after initial therapy.
Introduction
Papillary thyroid cancer (PTC) is characterized by a generally favorable prognosis, yet recurrence remains a persistent challenge that can manifest decades after treatment. To refine management strategies, the 2015 American Thyroid Association (ATA) guidelines introduced "Dynamic Risk Stratification" (DRS), which shifts focus from initial staging to a patient's ongoing response to therapy. The clinical "gold standard" is an Excellent Response (ER), defined by the absence of clinical, biochemical, or structural evidence of disease. Identifying early prognostic factors for ER is critical for personalizing follow-up and treatment intensity, yet previous research has often been limited by retrospective designs and conflicting results regarding the impact of lymph node metastasis.
Methods
This study utilized data from the prospective multicenter DTCC study (NCT02638077) conducted across nine medical institutions in China. Out of 2,013 initially enrolled patients, 506 met the inclusion criteria: confirmed PTC with lymph node metastasis and subsequent RAI therapy.
Patients followed a standardized protocol for surgery and RAI. Response to therapy was evaluated one year post-operation using the ATA reclassification system. Statistical modeling involved univariate and multivariable logistic regression to isolate independent risk factors. Additionally, ROC curve analysis was employed to establish numerical thresholds for metastatic lymph node counts that best predict the failure to achieve ER.
Key Results
One year after initial therapy, only 27.5% (139/506) of the cohort achieved an Excellent Response. Multivariable analysis identified three primary independent risk factors for the entire population:
- Extrathyroidal Extension (ETE): Odds Ratio (OR) = 1.644
- Number of Metastatic Lymph Nodes: OR = 1.042
- Ps-Tg Level (>2 ng/mL): OR = 3.317
The study established specific predictive cutoffs for metastatic lymph nodes. For the entire population, having more than 5 metastatic nodes predicted a non-excellent response (Sensitivity: 61.2%, Specificity: 54.5%). In the higher-risk pN1b subgroup (lateral neck metastasis), the optimal cutoff was more than 13 metastatic nodes (Sensitivity: 86.3%, Specificity: 35.4%).
Discussion and Key Insights
Several critical insights emerged from this prospective data:
- Ps-Tg as a Dominant Predictor: Preablative-stimulated thyroglobulin (Ps-Tg) levels above 2 ng/mL were the strongest predictor of failing to achieve ER. This likely reflects residual thyroid tissue or microscopic metastatic disease that persists after surgery but before RAI.
- Quantity Over Presence: While lymph node metastasis is common in PTC, the number of involved nodes is a far more precise prognostic tool than the mere presence of metastasis. This granularity allows for better risk stratification, particularly in N1b patients where the threshold for concern is higher (13 nodes).
- Subgroup Nuance: Risk factors vary by metastatic location. For N1a (central neck) patients, ETE and Ps-Tg are the primary drivers, whereas the absolute count of metastatic nodes becomes a critical independent factor for N1b patients.
Limitations and Future Directions
While providing robust prospective evidence, the study has limitations. The 1-year follow-up period is relatively short for a slow-growing cancer like PTC; longer-term studies are needed to confirm if these early markers predict 10-year outcomes. Additionally, the exclusion of low-risk patients (those not requiring RAI) means these findings apply specifically to more advanced cases. Future research should integrate these clinical markers with molecular data, such as BRAF V600E or TERT mutations, to create a comprehensive multi-modal prognostic model.
Summary updated